Last Posted: Jan 21, 2021
- Screening and Preventative Strategies for Patients at High Risk for Breast Cancer.
Ter-Minassian Monica et al. JCO oncology practice 2021 Jan OP2000262
- Pathogenicity Assessment of Variants for Breast Cancer Susceptibility Genes Based on BRCAness of Tumor Sample.
Yoshida Reiko et al. Cancer science 2021 Jan
- Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.
Watson Catherine H et al. Targeted oncology 2021 Jan
- Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner Janice L et al. Journal of genetic counseling 2021 Jan
- Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
Hodan Rachel et al. Cancer medicine 2020 Dec
- CanRisk Tool - A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.
Carver Tim et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020 Dec
- Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer.
Chávarri-Guerra Yanin et al. Journal of geriatric oncology 2020 Dec
- Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
Lee Daphne S-C et al. Journal of genetic counseling 2020 Nov
- Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
Rana Huma Q et al. Gynecologic oncology 2020 Nov
- Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
Leitsalu Liis et al. European journal of human genetics : EJHG 2020 Nov
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- CDC Information (13)
- NIH Information (8)
- COVID-19 (7)
- CDC Publications (3)
- Human Genome Epidemiologic Studies (1804)
- GWAS Studies (18)
- Human Genomics Translation/Implementation Studies (770)
- Genomic Tests Evidence Synthesis (65)
- Genomic Tests Guidelines (41)
- Tier-Classified Guidelines (22)
- Non-Genomics Precision Health (11)
- Pathogen Advanced Molecular Detection (4)
- State Public Health Genomics Programs (107)
- Reviews/Commentaries (336)
- Tools/Methods (13)
- Ethical/Legal and Social Issues (ELSI) (14)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.